Last Updated : May 6, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Simponi | Golimumab | Ulcerative colitis | Do not list at the submitted price | Complete | ||
| Inspra | Eplerenone | Heart failure, NYHA class II | Do not list at the submitted price | Complete | ||
| Erivedge | Vismodegib | Basal Cell Carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Erbitux | Cetuximab | Metastatic Colorectal Cancer | Do not reimburse | Complete | ||
| Giotrif | Afatinib | Advanced or Metastatic Non-Small Cell Lung Cancer | Reimburse | Complete | ||
| Jetrea | Ocriplasmin | Vitreomacular adhesion | List with criteria/condition | Complete | ||
| Komboglyze | Saxagliptin + metformin | Diabetes Mellitus, Type 2 | Withdrawn | |||
| Invokana | Canagliflozin | Diabetes Mellitus, Type 2 | Withdrawn | |||
| Alimta | Pemetrexed | Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Genotropin | Somatropin | Growth hormone deficiency, adult | List with criteria/condition | Complete |
Last Updated : May 6, 2024